AEON Biopharma Inc
AEON.WS
AEON.WS was delisted on the 26th of April, 2024.
51 hedge funds and large institutions have $7.04M invested in AEON Biopharma Inc in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 7 closing their positions.
7% less funds holding
Funds holding: 55 → 51 (-4)
14% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 7
16% less capital invested
Capital invested by funds: $8.42M → $7.04M (-$1.38M)
57% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Parallax Volatility Advisers
San Francisco,
California
|
+$153K |
| 2 |
AC
Aristeia Capital
Greenwich,
Connecticut
|
+$138K |
| 3 |
CF
Cantor Fitzgerald
New York
|
+$22K |
| 4 |
Nomura Holdings
Tokyo,
Japan
|
+$12.3K |
| 5 |
CC
Centiva Capital
New York
|
+$6.88K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Blackstone Inc
New York
|
-$85K |
| 2 |
ICMH
Integrity Capital Management (HK)
Central,
Hong Kong
|
-$35K |
| 3 |
RA
Ramius Advisors
New York
|
-$35K |
| 4 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$25K |
| 5 |
ACA
Arena Capital Advisors
Los Angeles,
California
|
-$22K |
AEON.WS Hedge Fund Activity: Q1 2022 in Review
51 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in AEON Biopharma Inc (AEON.WS) for Q1 2022, worth a combined $7.04M — down 16% from $8.42M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of AEON.WS and 3 opened new positions — a net loss of 4 holders — while 7 trimmed existing stakes and 6 added.
The largest buyer was Parallax Volatility Advisers, adding an estimated $153K. The largest seller was Blackstone Inc, exiting entirely with an estimated $85K sold.
- 51 institutional investors held AEON Biopharma Inc (AEON.WS) as of Q1 2022, down from 55 in Q4 2021.
- Funds reported $7.04M of AEON Biopharma Inc stock for Q1 2022, down 16% quarter-over-quarter.
- 3 funds opened new AEON Biopharma Inc positions in Q1 2022 and 7 closed out, a net change of -4 holders.
- The largest AEON Biopharma Inc buyer in Q1 2022 was Parallax Volatility Advisers, an estimated $153K added.
- The largest AEON Biopharma Inc seller in Q1 2022 was Blackstone Inc, an estimated $85K sold.
Based on aggregated 13F filings for Q1 2022.